Why Hims & Hers (HIMS) rose 8.11%
Hims & Hers (HIMS) rose 8.11% on November 6, 2026 — Lilly weight-loss drug tie-up boosts Hims.
What happened
Hims & Hers rose 8.1% after Eli Lilly announced a partnership to offer weight-loss drugs through the Hims & Hers platform. The deal gives the telehealth company access to a branded obesity treatment.
Why it moved
Adding a branded obesity drug from Lilly can expand subscriber growth and raise monetization per customer, which is what investors are pricing in.
Why it matters
This sits within the meme-stock theme, where high-retail-interest names rerate sharply on single headlines. Hims is trading as a retail favorite with a catalyst that gives its growth story a new leg.
What would break the thesis
If the partnership turns out to be narrow in scope or the economics leave margins thin, the stock could give back gains. Watch for details on pricing, volume commitments, and how much of the revenue Hims keeps.
Sources
- Lilly partners with Hims & Hers to offer weight-loss drugs — Investing.com